Claims for Patent: 10,329,571

Summary for Patent: 10,329,571

Title:	Dual cistronic bacterial expression system
Abstract:	The present invention relates to the dual, independent cistron expression system in a single vector for the production of protein of interest proteins and peptides expressed as insoluble inclusion bodies formed in the bacteria E. coli. The present invention also provides the process for the expression of protein of interest using said bicistronic vector.
Inventor(s):	Salunkhe; Shardul (Pune, IN), Varshney; Brajesh (Pune, IN), Soorapaneni; Sudheerbabu (Pune, IN)
Assignee:	Lupin Limited (Mumbai, IN)
Application Number:	15/324,105
Patent Claims:	1. A process for producing an antibody or fragment thereof comprising the steps of: (i) transforming a bacterial host cell with a single vector consisting of a dual cistronic expressions system comprising: a) a first cistron comprising a T7 promoter operably linked with a polynucleotide sequence encoding a heavy chain of an antibody or fragment thereof; and b) a second cistron comprising an arabinose promoter operably linked with a polynucleotide sequence encoding a light chain of an antibody or fragment thereof; (ii) culturing the transformed bacterial host cell in a suitable medium to simultaneously express the heavy and the light chains of the antibody or the fragment thereof, wherein the heavy and light chains are expressed at equimolar levels as inclusion bodies; and (iii) subjecting the inclusion bodies to a solubilization and refolding step to obtain a functional antibody or fragment thereof, wherein the recombinant dual cistronic vector encoding the light and heavy chains comprises the polynucleotide sequence set forth in SEQ ID NO: 19. 2. The process of claim 1, wherein the antibody fragment is Ranibizumab. 3. The process of claim 1, wherein the bacterial host cell is E. coli. 4. A process for producing Ranibizumab comprising the steps of: (i) transforming an E. coli host cell with a recombinant dual cistronic vector comprising SEQ ID NO: 19; (ii) culturing the transformed E. coli host cell in a suitable medium to express the heavy and light chains of Ranibizumab in inclusion bodies at equimolar levels; and (iii) subjecting the inclusion bodies to a solubilizing and refolding step to obtain a functional Ranibizumab.

Details for Patent 10,329,571

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006		2034-07-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012		2034-07-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016		2034-07-09
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018		2034-07-09